About LUMIGEN BIOTECHNOLOGY, INC.
Lumigen Biotechnology Inc is pioneering antibody-guided nanocomplexes to deliver powerful drugs deep inside tumors, including those shielded by the brain or dense tissue barriers. Their NOVVA™ platform is designed to overcome biological barriers that prevent current cancer drugs from reaching aggressive tumors.
Development of antibody-guided nanocomplexes for drug deliveryProprietary NOVVA™ platform for targeting aggressive solid tumorsPreclinical proof of concept in triple negative breast cancer and glioblastomaModular nanocomplex platform for drug delivery to brain tumors
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to LUMIGEN BIOTECHNOLOGY, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate, or want this page removed? Request a correction or removal.